169 related articles for article (PubMed ID: 30575334)
1. LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.
Maire V; Mahmood F; Rigaill G; Ye M; Brisson A; Némati F; Gentien D; Tucker GC; Roman-Roman S; Dubois T
Cancer Med; 2019 Jan; 8(1):325-336. PubMed ID: 30575334
[TBL] [Abstract][Full Text] [Related]
2. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
4. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
5. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.
den Hollander P; Rawls K; Tsimelzon A; Shepherd J; Mazumdar A; Hill J; Fuqua SA; Chang JC; Osborne CK; Hilsenbeck SG; Mills GB; Brown PH
Cancer Res; 2016 Apr; 76(7):1942-53. PubMed ID: 26921331
[TBL] [Abstract][Full Text] [Related]
6. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
[TBL] [Abstract][Full Text] [Related]
7. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
Qian J; Ma Y; Tahaney WM; Moyer CL; Lanier A; Hill J; Coleman D; Koupaei N; Hilsenbeck SG; Savage MI; Page BDG; Mazumdar A; Brown PH
Breast Cancer Res; 2024 Feb; 26(1):23. PubMed ID: 38317231
[TBL] [Abstract][Full Text] [Related]
8. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
[TBL] [Abstract][Full Text] [Related]
9. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
10. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
11. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
12. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.
Grieb BC; Chen X; Eischen CM
Mol Cancer Res; 2014 Sep; 12(9):1216-24. PubMed ID: 24866769
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
14. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
15. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
16. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
19. TIPIN depletion leads to apoptosis in breast cancer cells.
Baldeyron C; Brisson A; Tesson B; Némati F; Koundrioukoff S; Saliba E; De Koning L; Martel E; Ye M; Rigaill G; Meseure D; Nicolas A; Gentien D; Decaudin D; Debatisse M; Depil S; Cruzalegui F; Pierré A; Roman-Roman S; Tucker GC; Dubois T
Mol Oncol; 2015 Oct; 9(8):1580-98. PubMed ID: 26004086
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
